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The big picture and the little picture
The last quarter of 2005 and the beginning of 2006 have seen major changes in health
legislation in the UK. Following the lead of many countries from around the world
(New Zealand, Ireland, and Italy among others) the UK government, pushed along
by individual members of Parliament, have decided to ban smoking in enclosed public
spaces such as bars, pubs, and restaurants. This is a victory for the workers in these
places and members of the public who visit, and the wider healthcare community
who clearly expect there to be a decrease in smoking. One less obvious and yet more
important result is that now there is a clear, coherent, and unified message coming
from doctors, government, and workers that smoking is harmful and it should not
and cannot be tolerated in a modern society.
There will be a backlash from the tobacco companies. They might produce
“healthier than ever” cigarettes, they might reduce cost, or more likely they will
lobby very hard behind the scenes to limit damage and reduce the impact of the
strong public health statements being made. Moreover, the tobacco industry might
turn its back on the West and concentrate on the developing countries of the world
where there is increasing affluence and a fertile market for cigarettes, particularly
among younger women.
This is the big picture. The world is becoming a difficult place to sell cigarettes,
as more states in the US at least partially ban smoking and European countries
individually take action. So what about our patients? They form the little picture.
What is being done for them and for the future patients with COPD?
There is no wonder cure for COPD but there are effective therapies. These are
both drug-related and non-pharmacological. We are rapidly increasing our
understanding of the disease, both its basic mechanism and its physiology as a systemic
disease. For the individual COPD patient, small and individually insignificant
improvements will accrue and over time they will stabilize and possibly improve. Of
particular importance is nutrition. This rather neglected area now has been
demonstrated to be a key indicator of mortality and can be used as a response to
treatment.
Parallels could be drawn with the modern management of cystic fibrosis. Survival
of patients with this disease has risen significantly in the last 20 years and yet there
has been no major breakthrough, no cure. Small changes and attention to detail in
each individual patient have led to incremental improvements in lung function and
survival.
We must do the same for the COPD patient. We must concentrate on what patients
can achieve and encourage them to do more, we must give them the correct drug
regimen, we must help them get to and maintain an ideal bodyweight, and
exacerbations must be treated promptly and effectively. Through inspirational and
insightful research, new therapies will emerge, new management approaches will be
tried and tested, and, we hope, the lives and the expectations of our patients can be
slowly but surely improved.